B
Bright Peak Therapeutics
Biotech & Life Sciences · Basel, Switzerland · Founded 2017
Developing next-generation immunotherapies, focusing on the treatment of cancer and autoimmune diseases MoreLess
Bright Peak Therapeutics is at the forefront of developing next-generation immunotherapies, focusing on the treatment of cancer and autoimmune diseases. Utilizing a proprietary chemical protein synthesis platform, the company engineers multifunctional precision biologics designed to enhance immune responses. Bright Peak's business model revolves around advancing a robust portfolio of cytokine-based therapies, targeting both innate and adaptive immune systems. The company operates in the biopharmaceutical sector, serving healthcare providers and patients seeking advanced treatment options. Revenue is generated through the development and potential commercialization of these novel therapies. With operations in Basel, Switzerland, and Southern California, Bright Peak is committed to expanding its international presence and continues to recruit talent to support its growth. The company's strategic focus on protein engineering positions it as a key player in the immunotherapy market. Keywords: immunotherapy, protein synthesis, cytokine, cancer treatment, autoimmune diseases, biologics, immune response, biopharmaceutical, precision medicine, healthcare.
Company overview
Bright Peak Therapeutics company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2017
- Headquarters
- Basel, Switzerland
- Employees
- 37
- Open positions
- None listed
- Dealroom signal
- 62.7
Valuation & funding
Bright Peak Therapeutics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Jun 2024 | $90M | $535M | Fidelity Investments · Invus · Northleaf · RA Capital Management | ↗ |
| SERIES BOther financing | Jun 2021 | $107M | $428M | Alexandria Venture Investments · BlackRock · Fidelity Investments · Qatar Investment Authority | — |
| SERIES AOther financing | Jul 2020 | $35M | $140M | Versant Ventures | — |
| SPINOUTOther financing | Dec 2017 | $0 | — | ETH Zurich | ↗ |
Growth signals
Bright Peak Therapeutics website traffic
Latest recorded traffic for Bright Peak Therapeutics is 670 monthly website visits, down 70.9% over the last three months. Bright Peak Therapeutics's team declined 22.9% over the past year.
Comparisons
Bright Peak Therapeutics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Bright Peak Therapeutics's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Bright Peak Therapeutics has talent and traffic
team presence
In the news
Latest news about Bright Peak Therapeutics
Recent press, funding announcements, and product moves mentioning Bright Peak Therapeutics — open to read from the original sources.
Market sentiment
What the market is saying about Bright Peak Therapeutics
An AI-synthesized read of the highest-engagement posts about Bright Peak Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Bright Peak Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.